Concepedia

Eric Ople

EO

Statistics

Publications

4

Citations

194

H-Index

4

Active since

2017

Affiliations

Amplyx Pharmaceuticals (United States)(Current)

Pfizer (United States)

Eric Ople is an author at Amplyx Pharmaceuticals (United States) specializing in medicine, microbial pathogens, and drug safety.

Top concepts

Publications per year

2017–2023

4

Publications

4

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris <i>:</i> Results from a Phase 2 Trial

José A. Vázquez, Peter G. Pappas, Kenneth D Boffard et al. · Antimicrobial Agents and Chemotherapy · 2023 · 65 citations · Full text

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

Michael R. Hodges, Eric Ople, Karen Joy Shaw et al. · Open Forum Infectious Diseases · 2017 · 47 citations · Full text

, , +20

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Michael R. Hodges, Eric Ople, Pamela Wedel et al. · Antimicrobial Agents and Chemotherapy · 2023 · 42 citations · Full text

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Michael R. Hodges, Eric Ople, Karen Joy Shaw et al. · Open Forum Infectious Diseases · 2017 · 40 citations · Full text

, , +17

1–4 of 4